UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~June 3130, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

WILLIAMS ROWLAND ACQUISITION CORP.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-40659		86-2603800
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

450 Post Road East

Westport, CT

06880

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (203) 353-7610

N/A

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock WRAC NYSE American LLC Warrants WRAC WS ~~NYSE~~None ~~American LLC~~ Units WRAC U NYSE American LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of ~~May~~August 1918, 2023, 98,~~216~~347,~~135~~265 shares of common stock, par value $0.0001 per share, were issued and outstanding.

WILLIAMS ROWLAND ACQUISITION CORP.

FORM 10-Q FOR THE QUARTER ENDED ~~MARCH~~JUNE 3130, 2023

TABLE OF CONTENTS

	Page
Part I. Financial Information
Item 1. Financial Statements	1
Condensed Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022	1
Condensed Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022	1
Unaudited Condensed Statements of Operations for the Three Months Ended March 31, 2023 and 2022 (Unaudited)	2
Unaudited Condensed Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022 (Unaudited)	2
Condensed Statements of Changes in Stockholders’ Deficit for the Three Months Ended March 31, 2023 and 2022 (Unaudited)	3
Condensed Statements of Changes in Stockholders’ Deficit for the Three and Six Months Ended June 30, 2023 and 2022 (Unaudited)	3
Unaudited Condensed Statements of Cash Flows for the Three months Ended March 31, 2023 and 2022 (Unaudited)	4
Unaudited Condensed Statements of Cash Flows for the Six months Ended June 30, 2023 and 2022 (Unaudited)	4
Notes to Condensed Financial Statements (Unaudited)	5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	1718
Item 3. Quantitative and Qualitative Disclosures Regarding Market Risk	2122
Item 4. Controls and Procedures	2122
Part II. Other Information
Item 1. Legal Proceedings	2123
Item 1A. Risk Factors	2123
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds from Registered Securities	2123
Item 3. Defaults Upon Senior Securities	2123
Item 4. Mine Safely Disclosures	2123
Item 5. Other Information	2123
Item 6. Exhibits	2224
Part III. Signatures	2325

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

WILLIAMS ROWLAND ACQUISITION CORP.

CONDENSED BALANCE SHEETS

	March 31,			December 31,
	June 30,			December 31,
	2023			2022
	(Unaudited)
Assets
Current Assets
Cash	$	2197,~~674~~541		$	483,937
Prepaid expenses		~~184~~68,~~840~~753			214,912
Total current assets		~~187~~266,~~514~~294			698,849
Cash and Investments held in trust account		36,~~156~~574,~~852~~466			35,902,882
Total Assets	$	36,~~344~~840,~~366~~760		$	36,601,731
Liabilities and Stockholders’ Deficit
Current Liabilities
Accounts payable and accrued expenses	$	~~422~~543,~~629~~233		$	545,691
Income taxes payable		~~569~~708,~~126~~528			500,645
Promissory note – related party		~~675~~1,025,000			675,000
Total Current liabilities		12,~~666~~276,~~755~~761			1,721,336
Deferred underwriters’ discount		8,050,000			8,050,000
Total Liabilities		910,~~716~~326,~~755~~761			9,771,336
Commitments and Contingencies
Common stock subject to redemption, 3,466,135 shares at redemption value of $10.19 and $10.02 as of March 31, 2023 and December 31, 2022, respectively.		35,332,145			35,057,894
Common stock subject to redemption, 3,466,135 shares at redemption value of $10.30 and $10.02 as of June 30, 2023 and December 31, 2022, respectively.		35,710,480			35,057,894
Stockholders’ Deficit
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding		—			—
Common stock, $0.0001 par value; 100,000,000 shares authorized; 5,750,000 shares issued and outstanding (excluding 3,466,135 shares subject to possible redemption)		575			575
Additional paid-in capital		—			—
Accumulated deficit		(89,~~705~~197,~~109~~056	)		(8,228,074	)
Total Stockholders’ Deficit		(89,~~704~~196,~~534~~481	)		(8,227,499	)
Total Liabilities and Stockholders’ Deficit	$	36,~~344~~840,~~366~~760		$	36,601,731

The accompanying notes are an integral part of these unaudited condensed financial statements.

WILLIAMS ROWLAND ACQUISITION CORP.

CONDENSED STATEMENTS OF OPERATIONS

(UNAUDITED)

	For the Three Months Ended March 31,
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2023			2022			2023			2022
Formation and operating costs	$	~~516~~344,~~936~~470		$	~~448~~573,~~364~~385		$	861,408		$	1,021,749
Loss from operations		(~~516~~344,~~936~~470	)		(~~448~~573,~~364~~385	)		(861,408	)		(1,021,749	)
Other income:
Other income (expense):
Trust interest income		415,175			87,457
Interest expense		(79,896	)		—			(79,896	)		—
Total other income, net		415,175			87,457
Trust interest income		417,614			168,512			832,789			255,969
Loss before provision for income taxes		(101,761	)		(360,907	)
Total other income, net		337,718			168,512			752,893			255,969
Provision for income taxes		(101,024	)		—
Loss before provision for income taxes		(6,752	)		(404,873	)		(108,515	)		(765,780	)
Net loss	$	(202,785	)	$	(360,907	)
Provision for income taxes		(106,859	)		—			(207,883	)		—
Basic and diluted weighted average shares outstanding, common stock subject to redemption		3,466,135			23,000,000
Net loss	$	(113,611	)	$	(404,873	)	$	(316,398	)	$	(765,780	)
Basic and diluted net loss per share	$	(0.02	)	$	(0.01	)
Basic and diluted weighted average shares outstanding, common stock subject to redemption		3,466,135			23,000,000			3,466,135			23,000,000
Basic and diluted weighted average shares outstanding, non-redeemable common stock		5,750,000			5,750,000
Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)
Basic and diluted net loss per share	$	(0.02	)	$	(0.01	)
Basic and diluted weighted average shares outstanding, non-redeemable common stock		5,750,000			5,750,000			5,750,000			5,750,000
Basic and diluted net loss per share	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

WILLIAMS ROWLAND ACQUISITION CORP.

CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT

(UNAUDITED)

FOR THE THREE AND SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2023

					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance as of December 31, 2022		5,750,000	$	575	$	—	$	(8,228,074	)	$	(8,227,499	)
Remeasurement of Class A common stock to possible redemption		—		—		—		(274,251	)		(274,251	)
Remeasurement of common stock to possible redemption		—		—		—		(274,251	)		(274,251	)
Net loss		—		—		—		(202,785	)		(202,785	)
Balance as of March 31, 2023		5,750,000	$	575	$	—	$	(8,705,109	)	$	(8,704,534	)
Remeasurement of common stock to possible redemption		—		—		—		(378,336	)		(378,336	)
Net loss		—		—		—		(113,611	)		(113,611	)
Balance as of June 30, 2023		5,750,000	$	575	$	—	$	(9,197,056	)	$	(9,196,481	)

FOR THE THREE AND SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2022

					Additional					Total
	Common Stock				Paid-in		Accumulated			Stockholders’
	Shares		Amount		Capital		Deficit			Deficit
Balance as of December 31, 2021		5,750,000	$	575	$	—	$	(7,485,580	)	$	(7,485,005	)
Net loss		—		—		—		(360,907	)		(360,907	)
Balance as of March 31, 2022		5,750,000	$	575	$	—	$	(7,846,487	)	$	(7,845,912	)
Net loss		—		—		—		(404,873	)		(404,873	)
Balance as of June 30, 2022		5,750,000	$	575	$	—	$	(8,251,360	)	$	(8,250,785	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

WILLIAMS ROWLAND ACQUISITION CORP.

CONDENSED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Three Months Ended March 31,
	For the Six Months Ended June 30,
	2023			2022
Cash flows from operating activities:
Net loss	$	(~~202~~316,~~785~~398	)	$	(~~360~~765,~~907~~780	)
Adjustments to reconcile net loss to net cash used in operating activities:
Interest earned on marketable securities held in Trust Account		(~~415~~832,~~175~~789	)		(87255,~~457~~969	)
Changes in current assets and liabilities:
Prepaid expenses		30146,~~072~~159			92185,~~915~~286
Due from related party		—			—
Accrued payable and expenses		(~~123~~2,~~061~~456	)		~~159~~125,~~127~~804
Income taxes payable		68207,~~481~~883			—
Net cash used in operating activities		(~~642~~797,~~468~~601	)		(~~196~~710,~~322~~659	)
Cash flows from investing activities:
Redemption of trust investments to pay taxes		161,205			—
Net cash provided by investing activities		161,205			—
Net change in cash		(481,263	)		(196,322	)
Cash flows from financing activities:
Proceeds from issuance of promissory note to related party		350,000			250,000
Net cash provided by financing activities		350,000			250,000
Net change in cash		(286,396	)		(460,659	)
Cash, beginning of the period		483,937			613,068
Cash, end of the period	$	2197,~~674~~541		$	~~416~~152,~~746~~409
Supplemental disclosure of cash flow information:
Remeasurement of common stock to possible redemption	$	~~274~~652,~~251~~587		$	—
Income taxes paid	$	57,000			—

The accompanying notes are an integral part of these unaudited condensed financial statements.

WILLIAMS ROWLAND ACQUISITION CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1 — Organization and Business Operations

Williams Rowland Acquisition Corp. (the “Company”) is a blank check company incorporated as a Delaware corporation for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company has initiated discussions with a potential target, but has not selected any Business Combination target. The Company may pursue an initial business combination target in any business or industry.

As of ~~March~~June 3130, 2023, the Company had not commenced any operations. All activity for the period from March 10, 2021 (inception) through ~~March~~June 3130, 2023 relates to the Company’s formation and operation and the Initial Public Offering (“IPO” or “Public Offering”) and the pursuit of a business combination. The Company will not generate any operating revenues until after the completion of its Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash, the Trust Account (as defined below) and cash equivalents from the proceeds derived from the IPO. The Company has selected December 31 as its fiscal year end.

The Company’s sponsors are Williams Rowland Sponsor LLC, a Delaware limited liability company and WRAC Ltd (collectively, the “Sponsors”). The registration statement for the Company’s initial public offering was declared effective on July 26, 2021 (the “Effective Date”). On July 29, 2021, the Company consummated the initial public offering (the “Public Offering” or “IPO”) of 20,000,000 units (the “Units”), at $10.00 per unit, generating gross proceeds of $200,000,000 (see Note 3). The underwriters exercised their full over-allotment option to purchase an additional 3,000,000 Units on August 5, 2021.

Simultaneously with the closing of the IPO, the Company consummated the sale of 9,900,000 warrants to the Sponsor (the “Private Placement Warrant(s)”), at a price of $1.00 per Private Placement Warrant, generating gross proceeds of $9,900,000 (see Note 4). Each Private Placement Warrant is exercisable to purchase one share of Common stock at $11.50 per share. The Sponsor purchased an additional 1,200,000 Private Placement Warrants as a result of the underwriters’ exercise of their full over-allotment option on August 5, 2021.

Transaction costs of the IPO and subsequent over-allotment exercise amounted to $16,074,841, comprised of $4,600,000 of underwriting discount, $8,050,000 of deferred underwriting discount, fair value of founder shares transferred to Anchor Investors of $2,772,169 (as defined in Note 5), and $652,672 of other offering costs.

The Company’s Business Combination must be with one or more target businesses that together have a fair value equal to at least 80% of the net balance in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held and taxes payable on the income earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). There is no assurance that the Company will be able to successfully effect a Business Combination.

Following the closing of the IPO on July 29, 2021, and the subsequent full exercise of the underwriters’ over-allotment option on August 5, 2021 of $236,500,000 (comprised of $205,900,000 from the IPO and $30,600,000 from the over-allotment) from the net proceeds of the sale of the Units, including a portion of the proceeds from the sale of the Private Placement Warrants, $234,600,000 ($10.20 per Unit) was placed in the trust account (“Trust Account”) located in the United States with Continental Stock Transfer & Trust Company acting as trustee and $1,900,000 of the total proceeds of the public and private offering was deposited into the Company’s Operating Bank account on July 30, 2021. These funds ~~are~~were initially invested only in U.S. government securities with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury obligations. Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its franchise and income tax obligations (less up to $100,000 interest to pay dissolution expenses), the proceeds from the Public Offering and the sale of the Private Placement Warrants will not be released from the Trust Account until the earliest of (a) the completion of the initial Business Combination, (b) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (i) to modify the substance or timing of the ability of holders of the public shares to seek redemption in connection with the initial Business Combination or the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 18 months from the closing of the Public Offering or (ii) with respect to any other provision relating to stockholders’ rights or pre-Business Combination activity, and (c) the redemption of the public shares if the Company is unable to complete the initial Business Combination within 18 months from the closing of the Public Offering, subject to applicable law. The proceeds deposited in the Trust Account could become subject to the claims of the creditors, if any, which could have priority over the claims of the public stockholders.

The Company will provide its public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination either (i) in connection with a stockholder meeting called to approve the initial Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed initial Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under the law or stock exchange listing requirements. The Company will provide the public stockholders with the opportunity to redeem all or a portion of their public shares upon the completion of the initial Business Combination at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of two business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations described herein.

The shares of common stock subject to redemption are recorded at redemption value and classified as temporary equity, inIn accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 480 “Distinguishing Liabilities from Equity.” The Company will proceed with a Business Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of a Business Combination and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Business Combination.

The Company ~~will~~initially ~~have~~had only 18 months from ~~the~~ the closing of the Public Offering, or January 29, 2023 (the “Combination Period”) to complete the initial Business Combination. If the Company is unable to complete the initial Business Combination within the Combination Period, the Company will: (i) cease all ~~operations~~ operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter subject to lawfully available funds therefor, redeem 100% of the public shares, at a per-share price, payable in cash, equal to the aggregate ~~amount~~ amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its franchise and income taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the board of directors, dissolve and liquidate, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the ~~requirements~~ requirements of other applicable law. There will be no redemption rights or liquidating distributions with respect to the warrants, which will expire worthless if the Company fails to complete the initial Business Combination within the Combination Period.

On December 22, 2022, the Company held a special meeting of stockholders (the “Meeting’), At the Meeting, the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State (the “Charter Amendment”), giving the Company the right to the date by which the Company has to consummate a business combination up to six (6) times (the “Charter Amendment”), each such extension for an additional one (1) month period (each an “Extension”), from January 29, 2023 to July 29, 2023 (or, if not a business day, the next business day thereafter) (such date actually extended being referred to as the “Extended Termination Date”). In connection with the vote on the Charter Amendment at the Special Meeting, a total of 19,533,865 shares of common stock were submitted for redemption, for the total amount of $201,304,772, which was withdrawn from the Trust Account in December 2022.

On December 14, 2022, in connection with the ~~Extension~~ Extension the Company entered into Non-Redemption Agreements with certain stockholders which owned 2,431,454 of Common stock, pursuant to which these stockholders have committed not to redeem their redeemable shares during the vote. In consideration of this agreement, the Sponsor has agreed to transfer 345,674 of its common stock to the Non-Redeeming Stockholders (See Note 5 — Related Party Transactions below).

As approved by its stockholders at the Special Meeting of Stockholders of the Company held on July 24, 2023 (the “Special Meeting”) the Company filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on July 24, 2023 (the “Charter Amendment”), that (i) gives the Company the right to extend the date by which it has to consummate a business combination up to eight (8) times (the “Extension Amendment”), each such extension for an additional one (1) month period (each an “Extension”), from July 29, 2023 to March 29, 2024 (such date actually extended being referred to as the “Extended Termination Date”) and (ii) removed from the Charter the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets (as determined in accordance with Rule 3a51-1(g)(1) of the Securities Exchange Act of 1934, as amended) of less than $5,000,001 upon consummation of a Business Combination (the “Redemption Limitation”) in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the Redemption Limitation (the “Redemption Limitation Amendment”).

In connection with the approval of the Extension at the Special Meeting, the Sponsor or its designee agreed to deposit into the Trust Account as a loan (a “Contribution,” and the Sponsor or its designee making such Contribution, a “Contributor”), for each month of the Extension, an amount equal to the lesser of (i) $50,000 or (ii) $0.02 per public share multiplied by the number of public shares outstanding, for an aggregate deposit of up to $400,000 if all monthly Extensions are exercised. Contributions. The Contributions are be evidenced by a non-interest bearing, unsecured promissory note to the Contributor (the “Contribution Note”) and will be repayable by the Company upon the earlier of the consummation of a Business Combination or the liquidation of the Company (the “Maturity Date”). If the Company does not consummate a Business Combination by the Extended Termination Date (unless it has been further extended, any such promissory notes will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. A contribution of $50,000 was deposited in the Trust Account on July 27, 2023 to extend the Extended Termination Date to August 29, 2023.

The initial stockholders, Sponsors, executive officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to any founder shares and public shares they hold in connection with the completion of the initial Business Combination, (ii) waive their redemption rights with respect to any founder shares and public shares they hold in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the ability of holders of the public shares to seek redemption in connection with the initial Business Combination or the Company’s obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within the Combination Period or (B) with respect to any other provision relating to stockholders’ rights or pre-initial Business Combination activity and (iii) waive their rights to liquidating distributions from the Trust Account with respect to any founder shares they hold if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the Combination Period.

The Sponsors have agreed that it will be liable to the Company if and to the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.20 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.20 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act. However, the Company has not asked the Sponsors to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsors have sufficient funds to satisfy its indemnity obligations and believe that the Sponsors’ only assets are securities of the Company. Therefore, the Company cannot assure you that the Sponsors would be able to satisfy those obligations.

Liquidity, Capital Resources and Going Concern

As of ~~March~~June 3130, 2023, the Company had $2197,~~674~~541 in its operating bank account and working capital deficiency of $~~773~~1,~~906~~165,730.

The Company’s liquidity needs up to ~~March~~June 3130, 2023, had been satisfied through a capital contribution from the Sponsors of $25,000 (see Note 5) for the founder shares and the loan under an unsecured promissory note, from the Sponsors, initially of up to $600,000 to cover expenses related to the Initial Public Offering. This loan was repaid and cancelled upon consummation of IPO and is no longer available for liquidity needs as of ~~March~~June 3130, 2023.

The Company anticipates that the $2197,~~674~~541 outside of the Trust Account as of ~~March~~June 3130, 2023, will not be sufficient to allow the Company to operate until ~~July 29, 2023,~~ the Extended Termination Date, assuming that a Business Combination is not consummated during that time. Until consummation of its Business Combination, the Company will be using the funds not held in the Trust Account, and any additional Working Capital Loans (as defined in Note 5) from the initial stockholders, the Company’s officers and directors, or their respective affiliates (which is described in Note 5), for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the business combination.

On September 7, 2021, the Company executed a convertible promissory note to the Sponsors for an amount of $500,000 (the “Promissory Note”). The Promissory Note is a part of $1,000,000 working capital facility described in the Note 5. The Promissory Note is non-interest bearing and is repayable at the earlier of the date of when the Company consummates a Business Combination with another entity, the date on which the Company determines to liquidate or December 31, 2023. At the option of the Sponsors, in lieu of cash payment of the principal, the Sponsors may receive warrants to purchase Common Stock of the Company. The Company had borrowed $125,000 on November 15, 2021, under the Promissory Note, which remained outstanding as of ~~March~~June 3130, 2023 and December 31, 2022.

On June 29, 2022, the Company entered into a second promissory note to the Sponsor for the amount of $250,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $250,000 under this promissory note which was outstanding as of ~~March~~June 3130, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were ~~updated~~ updated to reflect its repayment at the earlier of the close of its initial business combination or August 31, 2023.

On September 20, 2022, the Company entered into a third promissory note to the Sponsor for the amount of $300,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $300,000 under this promissory note which was outstanding as of ~~March~~June 3130, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were updated to reflect its repayment at the earlier of the close of its initial business combination or August 31, 2023.

Both notes entered into in 2022 did not include conversion features.

~~The~~On ~~Company~~April ~~can~~12, ~~raise additional capital through Working Capital Loans from the initial stockholders~~2023, the Company’s ~~officers,~~entered ~~directors,~~into ~~or their respective affiliates (which is~~a ~~described~~fourth inpromissory ~~Note~~note ~~5),~~to orthe ~~through~~Sponsor ~~loans~~for ~~from~~the ~~third~~amount ~~parties. None~~ of ~~the Sponsors~~$150, ~~officers or directors are under any obligation to advance funds to, or to invest in, the Company~~000. IfThe ~~the~~note ~~Company~~ is ~~unable~~non-interest tobearing ~~raise~~and ~~additional~~is ~~capital,~~payable itat ~~may~~the beearlier ~~required~~of ~~to take additional measures~~the todate ~~conserve~~on ~~liquidity,~~ which ~~could~~the ~~include,~~Maker ~~but~~consummates ~~not~~an ~~necessarily~~initial bebusiness ~~limited~~combination ~~to,~~and ~~curtailing~~July ~~operations~~29, ~~suspending the pursuit of its business plan, and reducing overhead expenses~~2023. The Company ~~cannot~~borrowed ~~provide~~$150,000 ~~any~~under ~~assurance~~this ~~that~~promissory note ~~new~~which ~~financing~~was ~~will~~outstanding beas ~~available~~of toJune ~~it on commercially acceptable terms~~30, ~~if at all~~2023.

The Company has until July 29, 2023 or Extended Termination Date, to consummate a Business Combination. It is uncertain that it will be able consummate a Business Combination within the Combination Period. If a Business Combination is not consummated within the Combination Period, there will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance FASB Accounting Standards Update (“ASU”) Topic 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern”, management has determined that liquidity issues and capital constraints as described above, in addition to the mandatory liquidation, and subsequent dissolution, should the Company be unable to complete a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance date of these unaudited condensed financial statements. No adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after July 29, 2023. The unaudited condensed financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

On June 22, 2023, the Company entered into a fifth promissory note to the Sponsor for the amount of $200,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and July 29, 2023. The Company borrowed $200,000 under this promissory note which was outstanding as of June 30, 2023.

The Company can raise additional capital through Working Capital Loans from the initial stockholders, the Company’s officers, directors, or their respective affiliates (which is described in Note 5), or through loans from third parties. None of the Sponsors, officers or directors are under any obligation to advance funds to, or to invest in, the Company. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of its business plan, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

The Company has until August 29, 2023 (Extended Termination Date), to consummate a Business Combination. The Extended Termination Date may be further extended on a monthly basis upon deposit into the Trust Account of $50,000 per month. In no event may the Extended Termination Date be extended beyond March 29, 2024 without further stockholder approval. It is uncertain that it will be able to consummate a Business Combination within the Combination Period. If a Business Combination is not consummated within the Combination Period, there will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance FASB Accounting Standards Update (“ASU”) Topic 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern”, management has determined that liquidity issues and capital constraints as described above, in addition to the mandatory liquidation, and subsequent dissolution, should the Company be unable to complete a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance date of these unaudited condensed financial statements. No adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after August 29, 2024. The unaudited condensed financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Risks and Uncertainties

Impact of COVID-19

Management is currently evaluating the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s financial position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these unaudited condensed financial statements. The unaudited condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Impact of the Military Conflict in Ukraine

In February 2022, the Russian Federation and Belarus commenced a military action with the country of Ukraine. As a result of this action, various nations, including the United States, have instituted economic sanctions against the Russian Federation and Belarus. Further, the impact of this action and related sanctions on the world economy are not determinable as of the date of these unaudited condensed financial statements.

Inflation Reduction Act of 2022

On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.

Any redemption or other repurchase that occurs after December 31, 2022, in connection with a Business Combination, extension vote or otherwise, may be subject to the excise tax. Whether and to what extent the Company would be subject to the excise tax in connection with a Business Combination, extension vote or otherwise would depend on a number of factors, including (i) the fair market value of the redemptions and repurchases in connection with the Business Combination, extension or otherwise, (ii) the structure of a Business Combination, (iii) the nature and amount of any “PIPE” or other equity issuances in connection with a Business Combination (or otherwise issued not in connection with a Business Combination but issued within the same taxable year of a Business Combination) and (iv) the content of regulations and other guidance from the Treasury. In addition, because the excise tax would be payable by the Company and not by the redeeming holder, the mechanics of any required payment of the excise tax have not been determined. The foregoing could cause a reduction in the cash available on hand to complete a Business Combination and in the Company’s ability to complete a Business Combination.

Note 2 — Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and six months ended ~~March~~June 3130, 2023 are not necessarily indicative of the results that ~~may~~ may be expected through December 31, 2023 or any future periods.

The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Form 10-K filed by the Company with the SEC on April 18, 2023.

Emerging Growth Company

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s unaudited condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Use of Estimates

The preparation of unaudited condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had $2197,~~674~~541 and $483,937 in cash and no cash equivalents as of ~~March~~June 3130, 2023 and December 31, 2022, respectively.

Investment Held in Trust Account

The assets held in the Trust Account were held in cash and U.S. Treasury Bills with a maturity of 185 days or less at ~~March~~June 3130, 2023 and December 31, 2022, respectively. During the period ~~three months~~ ended ~~March~~June 3130, 2023, the Company withdrew from the Trust Account $161,205 to pay its tax obligations, including Delaware franchise tax, as well as federal and Connecticut income and capital taxes.

The Company classifies its United States Treasury securities as held-to-maturity in accordance with FASB ASC Topic 320 “Investments - Debt and Equity Securities.” Held-to-maturity securities are those securities which the Company has the ability and intent to hold until maturity. Held-to-maturity treasury securities are recorded at amortized cost and adjusted for the amortization or accretion of premiums or discounts.

A decline in the market value of held-to-maturity securities below cost that is deemed to be other than temporary, results in an impairment that reduces the carrying costs to such securities’ fair value. The impairment is charged to earnings and a new cost basis for the security is established. To determine whether an impairment is other than temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. Evidence considered in this assessment includes the reasons for the impairment, the severity and the duration of the impairment, changes in value subsequent to year-end, forecasted performance of the investee, and the general market condition in the geographic area or industry in which the investee operates.

Premiums and discounts are amortized or accreted over the life of the related held-to-maturity security as an adjustment to yield using the effective-interest method. Such amortization and accretion are included in the “Trust interest income” line item in the statements of operations. Interest income is recognized when earned.

Management has determined that there has been no impairment to carrying value of the assets held in the Trust Account as of ~~March~~June 3130, 2023, and December 31, 2022.

Offering Costs Associated with Initial Public Offering

The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A - “Expenses of Offering”. Offering costs consist of legal, accounting, underwriting and other costs incurred that are related to the IPO. Offering costs amounted to $16,074,841, for the costs related to the IPO and subsequent over-allotment, as well as fair value of founder shares transferred to Anchor Investors. ~~Total~~ Total amount of offering costs is allocated between redeemable shares and Public Warrants based on their relative fair values.

Fair Value of Financial Instruments

The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheets, primarily due to its short-term nature.

Fair Value Measurements

The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually.

The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities:

	Level 1 —	Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these securities does not entail a significant degree of judgment.

	Level 2 —	Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by market through correlation or other means.

	Level 3 —	Valuations based on inputs that are unobservable and significant to the overall fair value measurement.

Warrants

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in FASB ASC 480, Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considered whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, was conducted at the time warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not meet all of the criteria for equity classification, the warrants are required to be recorded at their initial fair value on the date of issuance, and each balance sheet date thereafter. The Company accounts for its outstanding warrants as equity-instruments since the initial public offering.

Derivative Financial Instruments

The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date. The Promissory Note of the Company entered into September 7, 2021 includes conversion feature, the value of which is de minimis as of ~~March~~June 3130, 2023 and December 31, 2022.

FASB ASC 470-20, Debt with Conversion and Other Options addresses the allocation of proceeds from the issuance of convertible debt into its equity and debt components. The Company applies this guidance to allocate IPO proceeds from the Units between common stock and warrants, using the residual method by allocating IPO proceeds first to fair value of the warrants and then common stock.

The Company accounts for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.

Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense. The value of the conversion feature included in the convertible promissory note was de minimis as of ~~March~~June 3130, 2023 and December 31, 2022.

Common Stock Subject to Possible Redemption

The Company accounts for its Common stock subject to possible redemption in accordance with the guidance in FASB ASC Topic 480 “Distinguishing Liabilities from Equity.” Common stock subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value. Conditionally redeemable Common stock (including Common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, Common stock is classified as Stockholders’ equity. The Company’s Common stock features certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of uncertain future events. Accordingly, Common stock subject to possible redemption is presented at redemption value as temporary equity, outside of the Stockholders’ deficit section of the Company’s balance sheets.

Immediately upon the closing of the IPO, the Company recognized the accretion from initial book value to redemption amount. Increases or decreases in the carrying amount of redeemable common stock are affected by charges against additional paid-in capital and accumulated deficit.

As of ~~March~~June 3130, 2023 and December 31, 2022, the common stock subject to possible redemption reflected in the balance sheets is reconciled in the following table:

Gross Proceeds from IPO	$	230,000,000
Less:
Issuance costs related to redeemable common stock		(15,262,797	)
Proceeds allocated to Public Warrants, based on the estimated fair value as of date of the IPO		(11,618,788	)
Plus:
Remeasurement of common stock to redemption value		31,481,585
Common stock subject to possible redemption (December 31, 2021)		234,600,000
Less:
Redemptions of common stock		(201,304,772	)
Plus:
Remeasurement of common stock to redemption value		1,762,666
Common stock subject to possible redemption (December 31, 2022)	$	35,057,894
Plus:
Remeasurement of common stock to redemption value		~~274~~652,~~251~~586
Common stock subject to possible redemption (March 31, 2023)	$	35,332,145
Common stock subject to possible redemption (June 30, 2023)	$	35,710,480

Net ~~Income (~~Loss) Per Common Share

The Company complies with the accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company applies the two-class method in calculating earnings per share. The contractual formula utilized to calculate the redemption amount approximates fair value. The Class feature to redeem at fair value means that there is effectively only one class of common stock. Changes in fair value are not considered a dividend for the purposes of the numerator in the earnings per share calculation. Net ~~income (~~loss) per share of common stock is computed by dividing ~~the~~ the pro rata net ~~income (~~loss) between the shares of redeemable common stock and the shares of non-redeemable common stock by the weighted ~~average~~ average number of shares of common stock outstanding for each of the periods. The calculation of diluted ~~income (~~loss) per share does not consider the effect of the warrants issued in connection with the IPO since the exercise of the warrants is contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

The following table reflects the calculation of basic and diluted net ~~income (~~loss) per common stock (in dollars, except per share amounts):

	For the Three Months Ended March 31,
	For the Three Months Ended June 30,												For the Six Months Ended June 30,
	2023						2022						2023						2022
	Common Stock subject to possible redemption			Non-redeemable common stock			Common Stock subject to possible redemption			Non-redeemable common stock
	Shares Subject to Redemption			Shares Not Subject to Redemption			Shares Subject to Redemption			Shares Not Subject to Redemption			Shares Subject to Redemption			Shares Not Subject to Redemption			Shares Subject to Redemption			Shares Not Subject to Redemption
Basic and diluted net loss per common stock
Numerator:
Allocation of net loss, as adjusted	$	(7642,~~266~~729	)	$	(~~126~~70,~~519~~882	)	$	(~~288~~323,~~726~~898	)	$	(7280,~~181~~975	)	$	(118,995	)	$	(197,403	)	$	(612,624	)	$	(153,156	)
Denominator:
Basic and diluted weighted average shares outstanding		3,466,135			5,750,000			23,000,000			5,750,000			3,466,135			5,750,000			23,000,000			5,750,000
Basic and diluted net loss per common stock	$	(0.0201	)	$	(0.0201	)	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	(0.03	)	$	(0.03	)	$	(0.03	)

Income Taxes

The Company accounts for income taxes under ASC 740, “Income Taxes.” ASC 740, Income Taxes, requires the recognition of deferred tax assets and liabilities for both the ~~expected~~ expected impact of differences between the unaudited condensed financial statements and tax basis of assets and liabilities and for the ~~expected~~ expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. As of ~~March~~June 3130, 2023 and December 31, 2022, the Company’s deferred tax asset had a full valuation allowance recorded against it. The effective tax rate differs from the statutory tax rate of 21% for the three ~~months~~ and ~~three~~six months ended ~~March~~June 3130, 2023 and 2022, due primarily to the valuation ~~allowance~~ allowance on the deferred tax assets and non-deductible penalties.

Our effective tax rate was (99.28)% and 0.00% for the three months ended March 31, 2023 and 2022, respectively.

ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition.

The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of ~~March~~June 3130, 2023 and December 31, 2022. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position.

The Company has identified the United States as its only “major” tax jurisdiction. The Company is subject to income taxation by major taxing authorities since inception. These examinations may include questioning the timing and amount of deductions, the nexus of income among various tax jurisdictions and compliance with federal and state tax laws. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation (FDIC) insurance coverage limit of $250,000. The Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.

Recent Accounting Standards

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company deferred the adoption of ASU 2020-06 and is currently assessing the impact, if any, it would have on its financial position, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on its unaudited condensed financial statements.

Note 3 — Initial Public Offering

Public Units

On July 29, 2021, the Company sold 20,000,000 Units at a purchase price of $10.00 per Unit for aggregate proceeds of $200,000,000. On August 5, 2021, the underwriters exercised the full over-allotment option, which resulted in the sale of an additional 3,000,000 Units and $30,000,000 in proceeds. This resulted in aggregate Units sold of 23,000,000 and aggregate proceeds of $230,000,000 from the IPO and subsequent over-allotment.

Each Unit consists of one share of Common stock, and one-half (1/2) of one warrant (“Public Warrant”). Each whole public warrant entitles the holder to purchase one share of Common stock at an exercise price of $11.50 per share, subject to adjustment.

On December 22, 2022, 19,533,865 shares of Common Stock were redeemed, with 3,466,135 shares outstanding as of December 31, 2022. On July 24, 2023, further 868,870 shares of Common Stock were redeemed, resulting in 2,597,265 shares outstanding as date of this report.

Note 4 — Private Placement

Simultaneously with the closing of the IPO on July 29, 2021, the Sponsor purchased an aggregate of 9,900,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant, for a purchase price of $9,900,000, in a private placement. In connection with the underwriters’ exercise of their full over-allotment option on August 5, 2021, the Sponsors purchased an additional 1,200,000 Private Placement Warrants for a purchase price of $1,200,000. This resulted in aggregate Private Placement Warrants of 11,100,000 sold for aggregate proceeds of $11,100,000 from the IPO and subsequent over-allotment.

Each Private Placement Warrant entitles the holder thereof to purchase one share of the Company’s Common stock at a price of $11.50 per share, subject to adjustment, and will expire worthless if the Company does not complete the initial Business Combination. A portion of the proceeds from the private placement was added to the proceeds from the IPO held in the Trust Account.

Note 5 — Related Party Transactions

Founder Shares

Upon inception the Sponsors paid $25,000 in exchange for 5,750,000 shares of common stock (the “Founder Shares”). The number of founder shares outstanding was determined based on the expectation that the total size of the Public Offering would be a maximum of 23,000,000 Units if the underwriter’s over-allotment option is exercised in full, and therefore that such founder shares would represent 20% of the outstanding shares after the Public Offering. Up to 750,000 of the founder shares were subject to forfeiture depending on the extent to which the underwriter’s over-allotment was exercised. The underwriters exercised their full over-allotment option on August 5, 2021, thereby making the 750,000 shares no longer subject to forfeiture.

On June 26, 2021, the Sponsor transferred 40,000 of Founder Shares to three of the Company’s directors and the Chief Financial Officer (“CFO”) in recognition of and compensation for their future services to the Company. The assignment of the Founder Shares to the Company’s directors and CFO is within the scope of FASB ASC Topic 718, “Compensation-Stock Compensation” (“ASC 718”). Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 40,000 Founder Shares granted to the Company’s directors and CFO was $295,698 or approximately $7.39 per share. The Founder Shares were assigned to directors and advisor effectively assigned subject to a performance condition (i.e., the consummation of a Business Combination). Compensation expense related to the Founder Shares is recognized only when the performance condition is probable of achievement under the applicable accounting literature. Stock-based compensation would be recognized at the date a Business Combination is considered probable in an amount equal to the number of Founder Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founder Shares. As of ~~March~~June 3130, 2023 and December 31, 2022, the Company has not yet entered into any definitive agreements in connection with any Business Combination. Any such agreements may be subject to certain conditions to closing, such as, for example, approval by the Company’s stockholders. As a result, the Company determined that the consummation of a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized.

Of the aggregate 23,000,000 Units sold in the Initial Public Offering, 1,980,000 Units were purchased by (i) D. E. Shaw Valence Portfolios, L.L.C., (ii) certain investment funds and accounts managed by Radcliffe Capital Management, L.P., and (iii) certain investment funds and accounts managed by Shaolin Capital Management LLC, unaffiliated qualified institutional buyers (the “Anchor Investors”). In connection with the closing of the Initial Public Offering, each Anchor Investor acquired from the Sponsors an indirect economic interest in certain Founder Shares (375,000 Founder Shares in the aggregate) at a purchase price of $0.0001 per share. The Company estimated the aggregate fair value of the Founder Shares attributable to the Anchor Investors to be $2,772,169 or approximately $7.39 per share. The excess of the fair value of the Founder Shares was determined to be a contribution to the Company from the Sponsor in accordance with Staff Accounting Bulletin (“SAB”) Topic 5T and an offering cost in accordance with SAB Topic 5A. Accordingly, the offering cost was recorded against additional paid-in capital.

On ~~December~~June 1422, ~~2022~~2023, Wrac, ~~the~~Ltd. ~~Company~~a ~~entered into~~Guernsey ~~Non-Redemption~~Limited ~~Agreements~~Liability ~~with~~Company ~~certain~~(“Seller”), ~~stockholders~~Williams ~~pursuant~~Rowland toSponsor, ~~which~~LLC, ~~these~~a ~~stockholders~~Delaware ~~have~~Limited ~~committed~~Liability ~~not~~Company ~~to redeem their redeemable~~(“Buyer”), ~~shares~~Jonathan inRowland ~~connection~~and ~~with~~David ~~the extension vote~~B. InWilliams ~~consideration~~(each, ofa ~~this~~“Party” ~~agreement~~and, collectively, the ~~Sponsor~~“Parties”) ~~has~~entered ~~agreed~~into ~~to transfer~~ a ~~portion of its~~Securities ~~Common~~Purchase ~~Stock~~Agreement to (the ~~Non-Redeeming~~“Agreement”) ~~Stockholders.~~pursuant ~~The~~to ~~Company~~which ~~estimated~~Seller ~~the~~transferred ~~aggregate fair value of the 345~~2,~~674~~514,663 ~~founders~~ shares ~~attributable to~~of the ~~Non-Redeeming~~common ~~Stockholders to be $1~~stock,~~733,871~~ orpar value $50.020001 per share. ~~The~~(the ~~excess~~“Common Stock”) of ~~the~~Williams ~~fair~~Rowland ~~value~~Acquisition ofCorp. (the ~~Founder~~“Registrant”) ~~Shares~~and ~~was determined~~5,550,000 warrants to bepurchase ashares ~~contribution~~of toCommon ~~the~~Stock ~~Company from~~ (the ~~Sponsor~~“Warrants” inand, ~~accordance~~collectively with ~~Staff~~the ~~Accounting~~Founder ~~Bulletin~~Shares, (the “~~SAB~~Securities”) ~~Topic 5T and an~~ ~~offering~~constituting ~~cost~~all inof ~~accordance~~the ~~with~~securities ~~SAB~~of ~~Topic~~SPAC ~~5A.~~owned ~~Accordingly,~~by the ~~offering~~Seller ~~cost~~or ~~was~~Jonathan ~~recorded~~Rowland ~~against~~for ~~additional~~a ~~paid-in~~payment ~~capital~~of $300,000.

On December 14, 2022, the Company entered into Non-Redemption Agreements with certain stockholders pursuant to which these stockholders have committed not to redeem their redeemable shares in connection with the extension vote. In consideration of this agreement, the Sponsor has agreed to transfer a portion of its Common Stock to the Non-Redeeming Stockholders. The Company estimated the aggregate fair value of the 345,674 founders shares attributable to the Non-Redeeming Stockholders to be $1,733,871 or $5.02 per share. The excess of the fair value of the Founder Shares was determined to be a contribution to the Company from the Sponsor in accordance with Staff Accounting Bulletin (“SAB”) Topic 5T and an offering cost in accordance with SAB Topic 5A. Accordingly, the offering cost was recorded against additional paid-in capital, the fourth quarter of 2022.

The Company used the Monte Carlo simulation model and the following assumptions in determining the fair value of founder shares transferred to the stockholders that did not redeem their redeemable shares at the extension meeting.

Inputs	As of December 14, 2022
Stock price	$	10.24
Volatility		8.1	%
Expected term to warrant expiration		0.6 years
Risk-free-rate		4.67	%
Dividend yield		0

The Company’s initial stockholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last reported sale price of the common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their shares of common stock for cash, securities or other property (except as described herein under the section of this prospectus entitled “Principal Stockholders - Restrictions on Transfers of Founder Shares and Private Placement Warrants”). Any permitted transferees will be subject to the same restrictions with respect to any founder shares. (the “Lock-up”).

Promissory Notes with Sponsor

The Sponsors agreed to loan the Company up to $600,000 to be used for a portion of the expenses of the Public Offering. This loan was non-interest bearing, unsecured and due at the earlier of August 31, 2021 or the closing of the Public Offering. This loan was repaid and cancelled upon consummation of IPO and is no longer available for liquidity needs as of ~~March~~June 3130, 2023.

In order to finance transaction costs in connection with an intended initial Business Combination, the Sponsors, an affiliate of the Sponsors or certain of the Company’s officers and directors may, but are not obligated to, loan the Company additional funds as may be required for working capital purposes (the “Working Capital Loans”). If the Company completes an initial Business Combination, the Company would repay such loaned amounts out of the proceeds of the Trust Account released to the Company. Otherwise, such loans would be repaid only out of funds held outside the Trust Account. In the event that the initial Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. Up to $1,000,000 of such loans may be convertible into Private Placement Warrants of the post Business Combination entity, at a price of $1.00 per warrant at the option of the lender. The warrants would be identical to the Private Placement Warrants issued to the Sponsors.

On September 7, 2021, the Company executed a Promissory Convertible Note with the Sponsor for an amount of $500,000, as part of the Working Capital Loan facility and under the aforementioned terms, including a conversion option. The Promissory Note is non-interest bearing and is repayable at the earlier of the date of when the Company consummates a Business Combination with another entity, the date on which the Company determines to liquidate or December 31, 2023. On November 15, 2021 the Company borrowed $125,000 under the Promissory Note, which was outstanding as of March 31, 2023 and December 31, 2022. The conversion option included in the Promissory Note is considered an embedded derivative and is remeasured at the end of each reporting period, using Monte Carlo simulation method. The value of the conversion feature was de minimis as of March 31, 2023 and December 31, 2022.14

On ~~June~~September 297, ~~2022~~2021, the Company ~~entered~~executed ~~into~~ a Convertible ~~second~~Promissory ~~promissory~~Note ~~note~~with to the Sponsor for ~~the~~an amount of $~~250~~500,000, as part of the Working Capital Loan facility and under the aforementioned terms, including a conversion option. The ~~note~~Promissory Note is non-interest bearing and is ~~payable~~repayable at the earlier of the date of when the Company consummates a Business Combination with another entity, the date on which the ~~Maker~~Company ~~consummates~~determines anto ~~initial~~liquidate ~~business~~or ~~combination~~December 31, ~~and~~2023. ~~January~~On 26November 15, ~~2023.~~2021 ~~The~~the Company borrowed $~~250~~125,000 under ~~this~~the ~~promissory note~~Promissory Note, which was outstanding as of ~~March~~June 3130, 2023 and December 31, 2022. OnThe ~~January~~conversion ~~20,~~option ~~2023,~~included in the ~~terms~~Promissory ofNote ~~repayment~~is ofconsidered ~~this~~an ~~note~~embedded ~~were~~derivative and is remeasured at the ~~amended~~end toof ~~extend~~each ~~its~~reporting ~~maturity~~period, ~~date~~using toMonte tCarlo ~~the~~simulation ~~earlier~~method. The value of the ~~close~~conversion offeature ~~its~~was ~~initial~~de ~~business~~minimis ~~combination~~as orof ~~August~~June 3130, 2023 and December 31, 2022.

On ~~September~~June 2029, 2022, the Company entered into a second ~~third~~ promissory note to the Sponsor for the amount of $~~300~~250,000. The note is non-interest bearing and is payable at the earlier of ~~the~~ the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $~~300~~250,000 under this ~~promissory~~ promissory note which was outstanding as of ~~March~~June 3130, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were amended to extend its maturity date to t the earlier of the close of its initial business combination or August 31, 2023.

On September 20, 2022, the Company entered into a third promissory note to the Sponsor for the amount of $300,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $300,000 under this promissory note which was outstanding as of June 30, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were amended to extend its maturity date to the earlier of the close of its initial business combination or August 31, 2023.

Both promissory notes entered into in 2022, totaling $550,000 do not contain conversion provisions.

On April 12, 2023, the Company entered into a fourth promissory note to the Sponsor for the amount of $150,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and July 29, 2023. The Company borrowed $150,000 under this promissory note which was outstanding as of June 30, 2023.

Both promissory notes entered into in 2023, totaling $350,000 do not contain conversion provisions.

Administrative Service Fee

The Company has entered into an administrative services agreement on July 26, 2021, commencing on that date, pursuant to which the Company will pay an affiliate of the Sponsors a total of $10,000 per month for office space, administrative and support services. Upon completion of the Company’s initial Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three and six months ended ~~March~~June 3130, 2023, the Company recorded $30,000 and $60,000, of administrative service fees, which are included in formation and operating costs in the accompanying statements of operations, respectively. For the three and six months ended ~~March~~June 3130, 2022, the Company recorded $30,000 and $60,000, of administrative service fees, inwhich ~~connection~~are ~~with~~included ~~this~~in ~~agreement. $10,000~~formation and $0operating ~~were~~costs ~~outstanding~~in ~~for~~ the ~~administrative~~accompanying ~~services~~statements atof ~~March~~operations, 31respectively. As of June 30, 2023 and at December 31, 2022, the Company had $10,000 and $0 outstanding balance for the administrative services, respectively.

Note 6 — Investments Held in Trust Account

At ~~March~~June 3130, 2023 and at December 31, 2022, the assets held in the Trust Account were held in U.S. Treasury Bills with a maturity of 185 days or less. During the ~~three~~period ~~months~~ ended ~~March~~ ~~31,~~June 30, 2023, the Company withdrew $161,205 from the Trust Account to pay for estimated taxes.

The carrying value, excluding gross unrealized holding loss and fair value of held to maturity securities on ~~March~~June 3130, 2023 and December 31, 2022 are as follows:

Amortized Cost and Carrying Value as of March 31, 2023

Gross Unrealized Gains

Gross Unrealized Losses

Fair Value as of December 31, 2022

Amortized Cost and Carrying Value as of June 30, 2023

Gross Unrealized Gains

Gross Unrealized Losses

Fair Value as of June 30, 2023

Cash held in Trust Account

~~982~~2,725

—

~~982~~2,725

U.S. Treasury Securities

36,~~155~~571,~~870~~741

310,~~656~~664

—

36,~~159~~582,~~526~~405

36,~~156~~574,~~852~~466

310,~~656~~664

—

36,~~160~~585,~~508~~130

	Amortized Cost and Carrying Value as of December 31, 2022		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value as of December 31, 2022
U.S. Treasury Securities	$	—	$	—	$	—	$	—
Cash held in Trust Account		35,902,882		—		—		35,902,882
	$	35,902,882	$	—	$	—	$	35,902,882

Note 7 — Commitments and Contingencies

Registration Rights

The holders of the founder shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any shares of common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans and upon conversion of the founder shares) will be entitled to registration rights pursuant to a registration rights agreement requiring the Company to register such securities for resale. The holders of these securities will be entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the Company’s completion of the initial Business Combination.

Underwriting Agreement

The Company granted the underwriter a 45-day option to purchase up to 3,000,000 additional Units to cover any over-allotments, if any, at the Public Offering price less the underwriting discounts and commissions. On August 5, 2021, the underwriter exercised the over-allotment option in full.

The underwriter was entitled to a cash underwriting discount of two percent (2%) of the gross proceeds of the Public Offering, or $4,000,000. The underwriter exercised the full over-allotment option on August 5, 2021 resulting in an additional $600,000 underwriting discount for an aggregate underwriting discount of $4,600,000 related to the IPO and subsequent over-allotment exercise.

Additionally, the underwriter will be entitled to a deferred underwriting discount of 3.5% (or $8,050,000) of the gross proceeds of the Public Offering upon the completion of the Company’s initial Business Combination.

Note 8 — Stockholders’ Deficit

Preferred Stock

The Company is authorized to issue 1,000,000 ~~shares~~ shares of preferred stock with a par value of $0.0001 per share. As of ~~March~~June 3130, 2023 and December 31, 2022, there were no shares of ~~preferred~~ preferred stock issued or outstanding.

Common Stock

The Company is authorized to issue 100,000,000 shares of Common stock with a par value of $0.0001 per share. Holders of the Common stock are entitled to one vote for each common stock. As of ~~March~~June 3130, 2023 and December 31, 2022, there were 5,750,000 shares of Common stock issued and outstanding, excluding 3,466,135 shares subject to possible redemption, which are presented as temporary equity, as of ~~March~~June 3130, 2023 and December 31, 2022, respectively.

Warrants

Each whole warrant will entitle the holder to purchase one share of the Company’s common stock at a price of $11.50 per share, subject to adjustment. In addition, if the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of common stock (with such issue price or effective issue price to be determined in good faith by the board of directors and, in the case of any such issuance to the initial stockholders or their affiliates, without taking into account any founder shares or private placement securities held by them, as applicable, prior to such issuance) (the “newly issued price”), the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the newly issued price.

The warrants will expire at 5:00 p.m., New York City time on the warrant expiration date, which is five years after the completion of the initial Business Combination or earlier upon redemption or liquidation. On the exercise of any warrant, the warrant exercise price will be paid directly to the Company and not placed in the Trust Account.

The Company will not be obligated to deliver any shares of common stock pursuant to the exercise of a warrant and will have no obligation to settle such warrant exercise unless a registration statement under the Securities Act with respect to the shares of common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company’s satisfying its obligations described below with respect to registration. No warrant will be exercisable and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such warrant will not be entitled to exercise such warrant and such warrant may have no value and expire worthless. In no event will the Company be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised warrants, the purchaser of a Unit containing such warrant will have paid the full purchase price for the Unit solely for the share of common stock underlying such Unit.

The Company is not registering the shares of common stock issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event later than 15 business days after the closing of the initial Business Combination, the Company will use its best efforts to file with the SEC a registration statement for the registration under the Securities Act of the shares of common stock issuable upon exercise of the warrants and thereafter will use its best efforts to cause the same to become effective within 60 business days following the initial Business Combination and to maintain a current prospectus relating to the common stock issuable upon exercise of the warrants, until the expiration of the warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the shares of common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a “cashless basis” in accordance with Section 3(a)(9) of the Securities Act or another exemption. If that exemption, or another exemption, is not available, holders will not be able to exercise their warrants on a cashless basis.

The warrants are no longer traded on a national securities exchange but are traded in the over the counter market.

Redemption of warrants

Once the warrants become exercisable, the Company may redeem the outstanding warrants:

●

in whole and not in part;

●

at a price of $0.01 per warrant;

●

upon a minimum of 30 days’ prior written notice of redemption (the “30-day redemption period”); and

●

if, and only if, the last reported sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

The Private Placement Warrants are identical to the Public Warrants sold as part of the Units in the Initial Public Offering, subject to limited exceptions.

Note 9 — Subsequent Events

The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements.

16On July 24, 2023, the Company held the Special Meeting in which the stockholders approved and filed an amendment to its Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on July 24, 2023 (the “Charter Amendment”), that (i) gives the Company the right to extend the date by which Williams Rowland has to consummate a business combination up to eight (8) times (the “Extension Amendment”), each such extension for an additional one (1) month period (each an “Extension”), from July 29, 2023 to March 29, 2024 (such date actually extended being referred to as the “Extended Termination Date”) and (ii) removed from the Charter the limitation that the Company may not redeem public shares to the extent that such redemption would result in the Company having net tangible assets of less than $5,000,001 upon consummation of a Business Combination (the “Redemption Limitation”) in order to allow the Company to redeem public shares irrespective of whether such redemption would exceed the Redemption Limitation (the “Redemption Limitation Amendment”).

In connection with the Special Meeting, a total of 868,870 shares of common stock were submitted for redemption, resulting in withdrawal of approximately $9.0 million from the Trust Account on July 27, 2023. The redemption payments are subject to the provision of the IR Act as described above and might be subject to 1% excise tax on the total amount of redemption payments made.

In connection with redemptions the Company withdrew $0.9 million to cover its obligations for income and franchise taxes.

In connection with the approval of the Extension Amendment at the Special Meeting of Stockholders of the Company held on July 24, 2023, the Sponsor or its designee agreed to deposit into the Trust Account as a Contribution for each month of the Extension, an amount equal to the lesser of (i) $50,000 or (ii) $0.02 per public share multiplied by the number of public shares outstanding, for an aggregate deposit of up to $400,000 if all monthly Extensions are exercised. Contributions. The Contributions are be evidenced by the non-interest bearing, unsecured Contribution Note to the Contributor and will be repayable by the Company upon the earlier of the consummation of a Business Combination or the liquidation of the Company. If the Company does not consummate a Business Combination by the Extended Date, any such promissory notes will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. A contribution of $50,000 was deposited in the Trust Account on July 27, 2023 thereby extending the Extended Termination Date to August 29, 2023.

On July 27, 2023, the Company entered into a fifth promissory note to the Sponsor for the amount of $200,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and March 29, 2024. The Company borrowed $200,000 under this promissory note which was outstanding as of the date of this report.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

References to the “Company,” “our,” “us” or “we” refer to Williams Rowland Acquisition Corp. The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto contained elsewhere in this report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We have based these forward-looking statements on our current expectations and projections about future events. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “continue,” or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those described in our other U.S. Securities and Exchange Commission (“SEC”) filings.

Overview

We are a blank check company incorporated as a Delaware corporation on March 10, 2021. We were incorporated for the purpose of effecting a Business Combination.

As of ~~March~~June 3130, 2023, we have not yet commenced operations. All activity for the period from March 10, 2021 (inception) through ~~March~~June 3130, 2023 relates to our formation and the initial public offering (the “Initial Public Offering”), which is described below, as well as the pursuit of a business combination. We will not generate any operating revenues until after the completion of our initial Business Combination, at the earliest. We generate non-operating income in the form of interest income from the proceeds held in the Trust Account. We have selected December 31 as our ~~fiscal~~ fiscal year end.

Our Sponsors are Williams Rowland Sponsor LLC, a Delaware limited liability company and WRAC, Ltd, a Guernsey company. The registration statement for our Initial Public Offering was declared effective on July 26, 2021. On July 29, 2021, we consummated the Initial Public Offering of 20,000,000 units (the “Units” and, with respect to the shares of Common Stock included in the Units offered, the “Public Shares”), at $10.00 per Unit, generating gross proceeds of $200 million. On August 5, 2021, the underwriter fully exercised its option and purchased 3,000,000 additional Units, generating gross proceeds of $30 million (the “Over-Allotment”).

Simultaneously with the closing of the Initial Public Offering, we consummated the Private Placement of 9,900,000 Private Placement Warrants, at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of approximately $9.9 million. Concurrent with the consummation of the Over-Allotment on August 5, 2021, the Sponsors purchased 1,200,000 additional Private Placement Warrants, generating proceeds of $1,200,000 in the Second Private Placement.

Transaction costs of the IPO and subsequent Over-Allotment exercise amounted to $16,074,841, comprised of $4,600,000 of underwriting discount, $8,050,000 of deferred underwriting discount, $2,772,169 of fair value of shares transferred to Anchor Investors, and $652,672 of other offering costs.

Upon the closing of the Initial Public Offering and the Private Placement on July 29, 2021, and the Over-Allotment and Second Private Placement on August 5, 2021, approximately $234.6 million ($10.20 per Unit) of the net proceeds of the Initial Public Offering and the Private Placement was placed in a Trust Account ~~with~~ with Continental Stock Transfer & Trust Company acting as trustee and invested in United States “government securities” ~~within~~ within the meaning of Section 2(a)(16) of the Investment Company Act of 1940, as amended, (the “Investment Company Act”) having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 promulgated under Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by us, until the earlier of: (i) 24 months after completion of the IPO at which time the investments will be held in the form of interest-bearing deposits; (ii) the completion of a Business Combination and (iiiii) the distribution of the Trust Account as described below.

Our management has broad discretion with respect to the specific application of the net proceeds of its Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.

If we are unable to complete a Business Combination ~~within~~by 18August ~~months~~29, ~~from~~2023 ~~the~~which ~~closing~~date ofmay ~~the~~be ~~Initial~~extended ~~Public~~on ~~Offering,~~a ormonthly ~~January~~basis to no later than March 29, ~~2023~~2024 (the “Combination Period”), we will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholder’s rights as stockholders (including the right to receive further liquidating distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject, in the case of clauses (ii) and (iii), our obligation under requirements of applicable law.

1718

Extension ~~Meeting~~Meetings

On December 22, 2022, the Company held a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting stockholders voted on and approved an amendment (the “Extension Amendment”) to the Company’s amended and restated certificate of incorporation to extend the deadline by which the Company must complete an initial business combination from January 29, 2023 to July 29, 2023 (or, if not a business day, to the next business day (the “Extended Date”). In connection with the approval of the Extension Amendment, the Company was ~~required~~ required to give holders of its shares of Common Stock sold to the public (the “Public Shares”) the right to redeem their shares. Holders of an aggregate of 19,533,865 Public Shares exercised their redemption rights and did not subsequently reverse that decision. The per share redemption price was $10.31. After the redemption, there was 3,466,135 Public Shares along with the 5,750,000 shares of Common Stock originally issued to the founders (the “Founders Shares”) that remained outstanding as of ~~March~~June 3130, 2023.

AtOn ~~March~~July 3124, 2023, the ~~remaining~~Company ~~balance~~held in the Special ~~trust~~Meeting ~~account~~in ~~after~~which the ~~redemptions~~stockholders inapproved ~~connection~~and ~~with~~filed ~~the~~an ~~Extension~~amendment ~~Amendment~~to ~~was~~its ~~$36,156,852.~~Amended ~~None~~and ofRestated ~~the~~Certificate ~~remaining~~of ~~funds~~Incorporation ~~held~~with inthe ~~trust~~Delaware ~~will~~Secretary beof ~~released~~State ~~from~~on July 24, 2023 (the ~~trust~~“Charter ~~account~~Amendment”), ~~other~~that ~~than~~(i) ~~interest~~gives ~~income~~the toCompany ~~pay~~the ~~any~~right ~~tax~~to ~~obligations~~extend ~~until~~ the ~~earlier~~date ofby which ~~(i)~~Williams ~~our~~Rowland ~~consummation of~~has ~~our~~to ~~initial~~consummate a business combination up to eight (8) times (the “Extension Amendment”), ~~and~~each ~~then~~such extension ~~only~~for inan ~~connection~~additional ~~with~~one ~~those~~(1) ~~shares~~month ofperiod ~~common~~(each ~~stock~~an ~~that~~“Extension”), ~~such~~from ~~stockholder~~July ~~properly~~29, ~~elected~~ 2023 to ~~redeem~~March 29, ~~subject~~2024 (such date actually extended being referred to as the ~~limitations~~“Extended ~~described~~Termination ~~herein,~~Date”) and (ii) removed from the ~~redemption~~Charter ofthe ~~our~~limitation ~~public~~that ~~shares~~the ifCompany may wenot ~~are~~redeem ~~unable~~public shares to ~~consummate~~the ~~our~~extent ~~initial business~~that ~~combination~~such byredemption ~~the~~would ~~Extended~~result ~~Date,~~in orthe ~~(iii)~~Company ifhaving wenet ~~seek~~tangible toassets ~~further~~of ~~amend~~less ~~our~~than ~~certificate~~$5,000,001 upon consummation of ~~incorporation~~a toBusiness ~~affect~~Combination (the ~~substance or~~“Redemption ~~timing~~Limitation”) ofin ~~our~~order ~~obligation~~to allow the Company to redeem ~~all~~ public shares irrespective ifof wewhether ~~cannot~~such ~~complete~~redemption anwould ~~initial~~exceed ~~business~~the ~~combination~~Redemption byLimitation ~~such~~(the ~~further~~“Redemption ~~extended~~Limitation Amendment”). In ~~date~~connection with the Special Meeting, a total of 868,870 shares of common stock were submitted for redemption.

In connection with the approval of the Extension Amendment at the Special Meeting of Stockholders of the Company held on July 24, 2023, the Sponsor or its designee agreed to deposit into the Trust Account as a Contribution for each month of the Extension, an amount equal to the lesser of (i) $50,000 or (ii) $0.02 per public share multiplied by the number of public shares outstanding, for an aggregate deposit of up to $400,000 if all monthly Extensions are exercised. Contributions. The Contributions are be evidenced by the non-interest bearing, unsecured Contribution Note to the Contributor and will be repayable by the Company upon the earlier of the consummation of a Business Combination or the liquidation of the Company. If the Company does not consummate a Business Combination by the Extended Date, any such promissory notes will be repaid only from funds held outside of the Trust Account or will be forfeited, eliminated or otherwise forgiven. A contribution of $50,000 was deposited in the Trust Account on July 27, 2023 to extend the Extended Termination Date to August 29, 2023.

At June 30, 2023, the remaining balance in the trust account after the redemptions in connection with the Extension Amendment was $35,710,480. None of the remaining funds held in trust will be released from the trust account, other than interest income to pay any tax obligations until the earlier of (i) our consummation of our initial business combination, and then only in connection with those shares of common stock that such stockholder properly elected to redeem, subject to the limitations described herein, (ii) the redemption of our public shares if we are unable to consummate our initial business combination by the Extended Date, or (iii) if we seek to further amend our certificate of incorporation to affect the substance or timing of our obligation to redeem all public shares if we cannot complete an initial business combination by such further extended date.

Liquidity, Capital Resources and Going Concern

As of ~~March~~June 3130, 2023, we had $2197,~~674~~541 in our operating bank account and working capital deficiency of $~~773~~1,~~906~~165,730.

Our liquidity needs up to ~~March~~June 3130, 2023, had ~~been~~ been satisfied through a capital contribution from the Sponsors of $25,000 (see Notes to the financial statements) for the founder shares ~~and~~ and the loan under an unsecured promissory note, from the Sponsors, initially of up to $600,000 to cover expenses related to the Initial ~~Public~~ Public Offering. This loan was repaid and cancelled upon consummation of IPO and is no longer available for liquidity needs as of ~~March 31~~June 30, 2023.

We anticipate that the $2197,~~674~~541 outside of the Trust Account as of ~~March~~June 3130, 2023, will not be sufficient to allow us to operate until the Extended Date, assuming that a Business Combination is not consummated during that time. Until consummation of our Business Combination, we will be using the funds not held in the Trust Account, and any additional Working Capital Loans from the initial stockholders, our officers and directors, or their respective affiliates, for identifying and evaluating prospective acquisition candidates, performing business due diligence on prospective target businesses, traveling to and from the offices, plants or similar locations of prospective target businesses, reviewing corporate documents and material agreements of prospective target businesses, selecting the target business to acquire and structuring, negotiating and consummating the business combination.

On September 7, 2021, we executed the Promissory Note to the Sponsors for an amount of $500,000. The Promissory Note is a part of $1,000,000 working capital facility described in the Note 5 to the financial statements. The Promissory Note is non-interest bearing and is repayable at the earlier of the date of when the Company consummates a Business Combination with another entity, the date on which the Company determines to liquidate or December 31, 2023. At the option of the Sponsors, in lieu of cash payment of the principal, the Sponsors may receive warrants to purchase Common Stock of the Company. On November 15, 2021 the Company borrowed $125,000 under the Promissory Note which remained outstanding as of ~~March~~June 3130, 2023 and December 31, 2022.

On June 29, 2022, the Company entered into a second promissory note to the Sponsor for the amount of $250,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $250,000 under this promissory note which was outstanding as of March 31, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were amended to extend its maturity date to the earlier of the close of its initial business combination or August 31, 2023.19

On ~~September~~June 2029, 2022, the Company entered into a ~~third~~ second promissory note to the Sponsor for the amount of $~~300~~250,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $~~300~~250,000 under this ~~promissory~~ promissory note which was outstanding as of ~~March~~June 3130, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were amended to extend its maturity date to r the earlier of the close of its initial business combination or August 31, 2023.

On September 20, 2022, the Company entered into a third promissory note to the Sponsor for the amount of $300,000. The note is non-interest bearing and is payable at the earlier of the date on which the Maker consummates an initial business combination and January 26, 2023. The Company borrowed $300,000 under this promissory note which was outstanding as of June 30, 2023 and December 31, 2022. On January 20, 2023, the terms of repayment of this note were amended to extend its maturity date to r the earlier of the close of its initial business combination or August 31, 2023.

Both promissory notes entered into in 2022, totaling $550,000 do not contain conversion provisions.

We can raise additional capital through Working Capital Loans from the initial stockholders, the Company’s officers, directors, or their respective affiliates or through loans from third parties. None of the Sponsors, officers or directors are under any obligation to advance funds to, or to invest in, the Company. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of its business plan, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all.

We have until the Extended Date to ~~consummate~~ consummate a Business Combination. It is uncertain that it will be able consummate a Business Combination within the Combination Period. If a Business Combination is not consummated within the Combination Period, there will be a mandatory liquidation and subsequent dissolution. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance FASB Accounting Standards Update (“ASU”) Topic 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern”, management has determined that the potential liquidity and capital constraints as described above, in addition to potential mandatory liquidation, and subsequent dissolution, should the Company be unable to complete a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern through the earlier of one year from the issuance date of these unaudited condensed financial statements or ~~July~~March 29, ~~2023~~2024. No adjustments have been made to the carrying amounts of assets and liabilities should the Company be required to liquidate after August ~~July~~ 29, 2023. The unaudited condensed financial statements do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.

Results of Operations

All of our activity from March 10, 2021 (inception) through ~~March~~June 3130, 2023, was in preparation for an Initial Public Offering, and since our Initial Public Offering, our activity has been limited to the search for a prospective initial Business Combination. We will not generate any operating revenues until the closing and completion of our initial Business Combination.

For the three months ended ~~March~~June 3130, 2023, we had a net loss of $~~202~~113,~~785~~611, which consisted of ~~trust~~formation ~~interest~~and ~~income~~operating costs of $~~415~~344,~~175~~470, ~~offset~~provision byfor income taxes of ~~formation~~$106,859 and ~~operating~~interest ~~costs~~expense of $~~516~~79,~~936~~896, ~~and~~offset ~~provision~~by ~~for~~trust interest income ~~taxes~~ of $~~101~~417,~~024~~614.

For the three months ended ~~March~~June 3130, 2022, we had a loss of $~~360~~404,~~907~~873, which consisted solely of formation and operating costs of $~~448~~573,~~364~~385, offset by trust interest income of $87168,~~457~~512.

For the six months ended June 30, 2023, we had a net loss of $316,398, which consisted of formation and operating costs of $861,408, provision for income taxes of $207,883 and interest expense of $79,896, offset by trust interest income of $832,789.

For the six months ended June 30, 2022, we had a loss of $765,780, which consisted solely of formation and operating costs of $1,021,749, offset by trust interest income of $255,969.

Contractual Obligations

Underwriting Agreement

The underwriter is entitled to $0.35 per unit, or approximately $7.0 million in the aggregate, which will be payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that that we complete a Business Combination, subject to the terms of the underwriting agreement.

In connection with the consummation of the Over-Allotment on August 5, 2021, the underwriter was paid an additional fee of $600,000 upon closing of the Over-Allotment and approximately $1.05 million in deferred underwriting commissions.

Total deferred underwriting commissions was $8,050,000 as ~~March~~June 3130, 2023 and December 31, 2022.

Administrative Support Agreement

We agreed to pay the Sponsor a total of $10,000 per month, commencing on the date of listing on the NYSE, for office space, utilities, secretarial and administrative support services provided to members of the management team. Upon completion of the initial Business Combination or our liquidation, we will cease paying these monthly fees.

Critical Accounting Policies and Estimates

This management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair value of financial instruments and accrued expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following as our critical accounting policies:

Offering costs associated with the Initial Public Offering

The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (“SAB”) Topic 5A-” Expenses of Offering”. Offering costs consist of legal, accounting, underwriting, fair value of founder shares transferred to Anchor Investors, and other costs incurred through the balance sheet date that are related to the IPO. Offering costs amounted to $16,074,841, for the Initial Public Offering and subsequent over-allotment. Total amount of Offering costs is allocated between redeemable shares and Public Warrants based on their relative fair values.

Net ~~Income (~~Loss) Per Share

The Company complies with the accounting and ~~disclosure~~ disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company applies the two-class method in calculating ~~earnings~~ earnings per share. The contractual formula utilized to calculate the redemption amount approximates fair value. The Class feature to redeem at fair value means that there is effectively only one class of common stock. Changes in fair value are not considered a dividend for the purposes of the numerator in the earnings per share calculation. Net ~~income (~~loss) per share of common stock is computed by dividing the pro rata net ~~income (~~loss) between the shares of redeemable common stock and the shares of non-redeemable common stock by the weighted average number of shares of common stock outstanding for each of the periods. The calculation of diluted ~~income (~~loss) per share does not consider the effect of the warrants issued in connection with the IPO since the exercise of the warrants is contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive.

Recent Accounting Pronouncements

In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2024 and should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. The Company deferred application of ASU 2020-06 and is currently assessing the impact, if any, that ASU 2020-06 would have on its financial position, results of operations or cash flows.

Off-Balance Sheet Arrangements

As of ~~March~~June 3130, 2023, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company we are not required to make disclosures under this Item.

Item 4. Controls and Procedures

Disclosure controls are procedures that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act, such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms. Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management, including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our “Certifying Officers”), the effectiveness of our disclosure controls and procedures as of ~~March~~June 3130, 2023, pursuant to Rule 13a-15(b) under the Exchange Act. ~~Based~~ Based upon that evaluation, our Certifying Officers concluded that, as of ~~March~~June 3130, 2023, our disclosure controls and procedures were not effective due to:

●

Failure to properly evaluate and account for complex financial instruments, including classification of common stock subject to possible redemption, recognition of the overallotment liability on the IPO date, evaluation of the accounting for a convertible promissory note, evaluation of fair value of shares issued to Anchor Investors and proper classification of amounts owing to related parties.

●

Failure to accrue Connecticut Capital tax and NYSE listing and annual fees in an appropriate and timely manner, overstatement of previously recorded amounts for Delaware Franchise tax, and FINRA fees, which necessitated the restatement of our March 31, 2022 Quarterly Report on Form 10-Q. Such restatement is included in the Note on Restatement of Previously Issued Financial Statements in the Annual Report on Form 10-K.

●

Failure to ensure completeness and accuracy of accruals, including unbilled legal expenses, as well as lack of review of the manual spreadsheet calculations.

~~These~~● ~~matters~~Failure ~~constitute~~to ~~material~~accrue ~~weaknesses in~~interest ~~our~~and ~~internal~~penalties ~~control~~related ~~over financial reporting. In light of these material weaknesses, we performed additional analysis as deemed necessary~~ to ~~ensure~~late ~~that~~payment our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of ~~operations and cash flows for the periods presented~~taxes.

These matters constitute material weaknesses in our internal control over financial reporting. They remain non remediated through the date of this report. In light of these material weaknesses, we performed additional analysis as deemed necessary to ensure that our financial statements were prepared in accordance with U.S. generally accepted accounting principles. Accordingly, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.

We do not expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2022

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

As a smaller reporting company we are not required to make disclosures under this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

2123

Item 6. Exhibits

Exhibit Number		Description
31.1*		Certification of ~~Co-~~Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification of ~~Co-~~Principal ~~Executive~~Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.3*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.1**		Certification of Co-Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of Co-Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.3**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		Inline XBRL Instance Document.
101.SCH*		Inline XBRL Taxonomy Extension Schema Document.
101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

2224

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	WILLIAMS ROWLAND ACQUISITION CORP.
Date: May 19, 2023	By:	/s/ David B. Williams
Date: August 21, 2023	By:	/s/ David B. Williams
	Name:	David B. Williams
	Title:	~~Co-~~Chief Executive Officer
		(Principal Executive Officer)

Date: May 19, 2023	By:	/s/ Jonathan D. Rowland
Date: August 21, 2023	By:	/s/ Bobby Morovati
	Name:	~~Jonathan~~Bobby ~~D. Rowland~~Morovati
	Title:	~~Co-~~Chief ~~Executive~~Financial Officer
		(Principal Executive Officer)
		(Principal Financial Officer)

Date: May 19, 2023	By:	/s/ Bobby Morovati
	Name:	Bobby Morovati
	Title:	Chief Financial Officer
		(Principal Financial Officer)

23 NONE 23000000 23000000 3466135 3466135 0.01 0.01 0.03 0.03 5750000 5750000 5750000 5750000 0.01 0.01 0.03 0.03 23000000 23000000 3466135 3466135 5750000 5750000 5750000 5750000 0.01 0.01 0.01 0.01 0.03 0.03 0.03 0.03 false --12-31 Q2 0001855168 0001855168 2023-01-01 2023-06-30 0001855168 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001855168 wrac:WarrantsMember 2023-01-01 2023-06-30 0001855168 wrac:UnitsMember 2023-01-01 2023-06-30 0001855168 2023-08-18 0001855168 2023-06-30 0001855168 2022-12-31 0001855168 2023-04-01 2023-06-30 0001855168 2022-04-01 2022-06-30 0001855168 2022-01-01 2022-06-30 0001855168 wrac:CommonStockSubjectToRedemptionMember 2023-04-01 2023-06-30 0001855168 wrac:CommonStockSubjectToRedemptionMember 2022-04-01 2022-06-30 0001855168 wrac:CommonStockSubjectToRedemptionMember 2023-01-01 2023-06-30 0001855168 wrac:CommonStockSubjectToRedemptionMember 2022-01-01 2022-06-30 0001855168 wrac:NonredeemableCommonStockMember 2023-04-01 2023-06-30 0001855168 wrac:NonredeemableCommonStockMember 2022-04-01 2022-06-30 0001855168 wrac:NonredeemableCommonStockMember 2023-01-01 2023-06-30 0001855168 wrac:NonredeemableCommonStockMember 2022-01-01 2022-06-30 0001855168 us-gaap:CommonStockMember 2022-12-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001855168 us-gaap:RetainedEarningsMember 2022-12-31 0001855168 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001855168 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001855168 2023-01-01 2023-03-31 0001855168 us-gaap:CommonStockMember 2023-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001855168 us-gaap:RetainedEarningsMember 2023-03-31 0001855168 2023-03-31 0001855168 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001855168 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001855168 us-gaap:CommonStockMember 2023-06-30 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001855168 us-gaap:RetainedEarningsMember 2023-06-30 0001855168 us-gaap:CommonStockMember 2021-12-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001855168 us-gaap:RetainedEarningsMember 2021-12-31 0001855168 2021-12-31 0001855168 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001855168 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001855168 2022-01-01 2022-03-31 0001855168 us-gaap:CommonStockMember 2022-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001855168 us-gaap:RetainedEarningsMember 2022-03-31 0001855168 2022-03-31 0001855168 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001855168 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001855168 us-gaap:CommonStockMember 2022-06-30 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001855168 us-gaap:RetainedEarningsMember 2022-06-30 0001855168 2022-06-30 0001855168 us-gaap:IPOMember 2021-07-01 2021-07-29 0001855168 us-gaap:IPOMember 2021-07-29 0001855168 us-gaap:OverAllotmentOptionMember 2021-08-01 2021-08-05 0001855168 us-gaap:PrivatePlacementMember 2023-06-30 0001855168 us-gaap:PrivatePlacementMember 2023-01-01 2023-06-30 0001855168 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-06-30 0001855168 wrac:SponsorMember 2021-08-01 2021-08-05 0001855168 us-gaap:IPOMember 2023-06-30 0001855168 wrac:BusinessCombinationMember 2023-06-30 0001855168 2021-08-01 2021-08-05 0001855168 us-gaap:IPOMember 2021-08-01 2021-08-05 0001855168 2021-07-01 2021-07-30 0001855168 wrac:NonredeemableCommonStockMember 2022-12-14 0001855168 wrac:SponsorMember 2022-12-14 0001855168 wrac:BusinessCombinationMember 2023-07-24 2023-07-24 0001855168 wrac:SponsorMember 2023-01-01 2023-06-30 0001855168 wrac:SponsorMember 2023-06-30 0001855168 us-gaap:SubsequentEventMember 2023-07-27 2023-07-27 0001855168 wrac:PublicWarrantMember 2023-06-30 0001855168 wrac:SponsorMember 2023-06-30 0001855168 wrac:SponsorMember 2021-09-07 0001855168 wrac:SponsorMember 2021-09-01 2021-09-07 0001855168 2021-11-15 0001855168 wrac:SecondPromissoryNoteMember 2021-06-29 0001855168 wrac:SecondPromissoryNoteMember 2023-01-01 2023-06-30 0001855168 wrac:SecondPromissoryNoteMember 2022-01-01 2022-12-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-09-20 0001855168 wrac:ThirdPromissoryNoteMember 2023-01-01 2023-06-30 0001855168 wrac:ThirdPromissoryNoteMember 2022-01-01 2022-12-31 0001855168 wrac:FourthPromissoryNoteMember 2023-04-12 0001855168 wrac:FourthPromissoryNoteMember 2023-01-01 2023-06-30 0001855168 2023-06-22 0001855168 us-gaap:SubsequentEventMember 2023-08-29 2023-08-29 0001855168 2022-08-01 2022-08-16 0001855168 2021-01-01 2021-12-31 0001855168 2022-01-01 2022-12-31 0001855168 us-gaap:CommonClassAMember 2023-04-01 2023-06-30 0001855168 us-gaap:CommonClassBMember 2023-04-01 2023-06-30 0001855168 us-gaap:CommonClassAMember 2022-04-01 2022-06-30 0001855168 us-gaap:CommonClassBMember 2022-04-01 2022-06-30 0001855168 us-gaap:CommonClassAMember 2023-01-01 2023-06-30 0001855168 us-gaap:CommonClassBMember 2023-01-01 2023-06-30 0001855168 us-gaap:CommonClassAMember 2022-01-01 2022-06-30 0001855168 us-gaap:CommonClassBMember 2022-01-01 2022-06-30 0001855168 2021-07-01 2021-07-29 0001855168 us-gaap:IPOMember 2023-01-01 2023-06-30 0001855168 wrac:PublicWarrantMember 2023-06-30 0001855168 2022-12-22 0001855168 us-gaap:SubsequentEventMember 2023-07-24 0001855168 us-gaap:IPOMember 2021-07-20 2021-07-29 0001855168 us-gaap:PrivatePlacementMember 2021-07-20 2021-07-29 0001855168 wrac:SponsorsMember 2021-08-01 2021-08-05 0001855168 wrac:FounderSharesMember 2023-01-01 2023-06-30 0001855168 wrac:FounderSharesMember 2023-06-30 0001855168 wrac:FounderSharesMember us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0001855168 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-06-30 0001855168 2021-06-26 0001855168 wrac:FounderSharesMember 2021-06-26 0001855168 2023-06-01 2023-06-22 0001855168 us-gaap:CommonStockMember 2023-06-22 0001855168 us-gaap:CommonStockMember 2023-06-01 2023-06-22 0001855168 wrac:FounderSharesMember 2023-06-30 0001855168 wrac:FounderSharesMember us-gaap:IPOMember 2023-06-30 0001855168 2022-12-14 0001855168 2022-12-01 2022-12-14 0001855168 wrac:ProposedPublicOfferingMember 2023-01-01 2023-06-30 0001855168 wrac:BusinessCombinationMember 2023-01-01 2023-06-30 0001855168 2021-09-07 0001855168 wrac:SecondPromissoryNoteMember 2022-06-29 0001855168 wrac:SecondPromissoryNoteMember 2023-06-30 0001855168 wrac:SecondPromissoryNoteMember 2022-12-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-09-20 0001855168 wrac:ThirdPromissoryNoteMember 2023-06-30 0001855168 wrac:ThirdPromissoryNoteMember 2022-12-31 0001855168 wrac:FourthPromissoryNoteMember 2023-04-12 0001855168 wrac:FourthPromissoryNoteMember 2023-06-30 0001855168 wrac:FifthPromissoryNoteMember 2023-06-22 0001855168 wrac:FifthPromissoryNoteMember 2023-06-30 0001855168 wrac:SponsorsMember 2021-07-26 2021-07-26 0001855168 2022-12-14 2022-12-14 0001855168 wrac:AmortizedCostAndCarryingValueMember 2023-06-30 0001855168 wrac:GrossUnrealizedGainsMember 2023-06-30 0001855168 wrac:GrossUnrealizedLossesMember 2023-06-30 0001855168 wrac:FairValueMember 2023-06-30 0001855168 wrac:AmortizedCostAndCarryingValueMember 2022-12-31 0001855168 wrac:GrossUnrealizedGainsMember 2022-12-31 0001855168 wrac:GrossUnrealizedLossesMember 2022-12-31 0001855168 wrac:FairValueMember 2022-12-31 0001855168 us-gaap:PreferredStockMember 2023-06-30 0001855168 us-gaap:PreferredStockMember 2022-12-31 0001855168 2023-07-24 2023-07-24 0001855168 us-gaap:SubsequentEventMember 2023-07-24 2023-07-24 0001855168 2023-07-01 2023-07-27 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Williams Rowland Acquisition Corp. 23000000 3466135 0.01 0.02 5750000 5750000 0.01 0.02 23000000 3466135 5750000 5750000 0.01 0.01 0.02 0.02 false --12-31 Q1 0001855168 0001855168 2023-01-01 2023-03-31 0001855168 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001855168 wrac:WarrantsMember 2023-01-01 2023-03-31 0001855168 wrac:UnitsMember 2023-01-01 2023-03-31 0001855168 2023-05-19 0001855168 2023-03-31 0001855168 2022-12-31 0001855168 2022-01-01 2022-03-31 0001855168 wrac:CommonStockSubjectToRedemptionMember 2023-01-01 2023-03-31 0001855168 wrac:CommonStockSubjectToRedemptionMember 2022-01-01 2022-03-31 0001855168 wrac:NonredeemableCommonStockMember 2023-01-01 2023-03-31 0001855168 wrac:NonredeemableCommonStockMember 2022-01-01 2022-03-31 0001855168 us-gaap:CommonStockMember 2022-12-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001855168 us-gaap:RetainedEarningsMember 2022-12-31 0001855168 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001855168 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001855168 us-gaap:CommonStockMember 2023-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001855168 us-gaap:RetainedEarningsMember 2023-03-31 0001855168 us-gaap:CommonStockMember 2021-12-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001855168 us-gaap:RetainedEarningsMember 2021-12-31 0001855168 2021-12-31 0001855168 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001855168 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001855168 us-gaap:CommonStockMember 2022-03-31 0001855168 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001855168 us-gaap:RetainedEarningsMember 2022-03-31 0001855168 2022-03-31 0001855168 us-gaap:IPOMember 2021-07-01 2021-07-29 0001855168 us-gaap:IPOMember 2021-07-29 0001855168 us-gaap:OverAllotmentOptionMember 2021-08-01 2021-08-05 0001855168 us-gaap:PrivatePlacementMember 2023-03-31 0001855168 us-gaap:PrivatePlacementMember 2023-01-01 2023-03-31 0001855168 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-03-31 0001855168 wrac:SponsorMember 2021-08-01 2021-08-05 0001855168 us-gaap:IPOMember 2023-03-31 0001855168 wrac:BusinessCombinationMember 2023-03-31 0001855168 2021-08-01 2021-08-05 0001855168 us-gaap:IPOMember 2021-08-01 2021-08-05 0001855168 2021-07-01 2021-07-30 0001855168 wrac:NonredeemableCommonStockMember 2023-03-31 0001855168 wrac:SponsorMember 2023-03-31 0001855168 wrac:PublicWarrantMember 2023-03-31 0001855168 wrac:SponsorMember 2021-09-07 0001855168 wrac:SponsorMember 2021-09-01 2021-09-07 0001855168 2021-11-15 0001855168 wrac:SecondPromissoryNoteMember 2021-06-29 0001855168 wrac:SecondPromissoryNoteMember 2023-03-31 0001855168 wrac:SecondPromissoryNoteMember 2022-12-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-09-20 0001855168 wrac:ThirdPromissoryNoteMember 2023-03-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-12-31 0001855168 2022-01-01 2022-12-31 0001855168 2021-01-01 2021-12-31 0001855168 wrac:RedeemableCommonStockMember 2023-01-01 2023-03-31 0001855168 wrac:RedeemableCommonStockMember 2022-01-01 2022-03-31 0001855168 2021-07-01 2021-07-29 0001855168 us-gaap:IPOMember 2023-01-01 2023-03-31 0001855168 wrac:PublicWarrantMember 2023-03-31 0001855168 2022-12-22 0001855168 us-gaap:IPOMember 2021-07-20 2021-07-29 0001855168 us-gaap:PrivatePlacementMember 2021-07-20 2021-07-29 0001855168 wrac:SponsorsMember 2021-08-01 2021-08-05 0001855168 wrac:FounderSharesMember 2023-01-01 2023-03-31 0001855168 wrac:FounderSharesMember 2023-03-31 0001855168 wrac:FounderSharesMember us-gaap:OverAllotmentOptionMember 2023-01-01 2023-03-31 0001855168 us-gaap:OverAllotmentOptionMember 2023-01-01 2023-03-31 0001855168 2021-08-02 2021-08-05 0001855168 2021-06-26 0001855168 wrac:FounderSharesMember 2021-06-26 0001855168 wrac:FounderSharesMember 2023-03-31 0001855168 wrac:FounderSharesMember us-gaap:IPOMember 2023-03-31 0001855168 2022-12-14 0001855168 2022-12-01 2022-12-14 0001855168 wrac:ProposedPublicOfferingMember 2023-01-01 2023-03-31 0001855168 wrac:BusinessCombinationMember 2023-01-01 2023-03-31 0001855168 2021-09-07 0001855168 wrac:SecondPromissoryNoteMember 2022-06-29 0001855168 wrac:SecondPromissoryNoteMember 2023-03-31 0001855168 wrac:SecondPromissoryNoteMember 2022-12-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-09-20 0001855168 wrac:ThirdPromissoryNoteMember 2023-03-31 0001855168 wrac:ThirdPromissoryNoteMember 2022-12-31 0001855168 wrac:SponsorsMember 2021-07-26 2021-07-26 0001855168 wrac:FounderSharesMember 2022-12-31 0001855168 wrac:FounderSharesMember 2022-01-01 2022-12-31 0001855168 wrac:AmortizedCostAndCarryingValueMember 2023-03-31 0001855168 wrac:GrossUnrealizedGainsMember 2023-03-31 0001855168 wrac:FairValueMember 2023-03-31 0001855168 wrac:AmortizedCostAndCarryingValueMember 2022-12-31 0001855168 wrac:GrossUnrealizedGainsMember 2022-12-31 0001855168 wrac:GrossUnrealizedLossesMember 2022-12-31 0001855168 wrac:FairValueMember 2022-12-31 0001855168 us-gaap:OverAllotmentOptionMember 2021-08-02 2021-08-05 0001855168 us-gaap:IPOMember 2021-08-02 2021-08-05 0001855168 us-gaap:PreferredStockMember 2023-03-31 0001855168 us-gaap:PreferredStockMember 2022-12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

Filing Compare · Williams Rowland Acquisition Corp.